Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them.

Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals, vaccines, and animal health, continues to focus on innovation across oncology, cardiovascular, infectious diseases, and immunology. In 2025, the company is strategically preparing for the anticipated U.S. patent expiration of its blockbuster cancer therapy, Keytruda, in 2028. To address this, MRK announced a $3 billion cost-cutting and reinvestment plan aimed at funneling resources into high-priority growth areas such as oncology and cardiometabolic diseases by 2027.

Clinical advancements remain central to Merck & Co., Inc. (NYSE:MRK)’s strategy. At the European Society of Cardiology Congress 2025, the firm presented new data on cardiovascular conditions, including atherosclerotic cardiovascular disease, pulmonary hypertension, and heart failure with reduced ejection fraction. Notably, pooled analyses of Phase 3 VICTOR and VICTORIA trials for VERQUVO (vericiguat) demonstrated reductions in cardiovascular death and heart failure hospitalizations. Additionally, MRK reported positive topline results from Phase 3 CORALreef trials of Enlicitide Decanoate for hyperlipidemia and secured FDA approval for ENFLONSIA, a preventive RSV therapy for infants, supported by CDC guidance.

Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028

360b / Shutterstock.com

Merck & Co., Inc. (NYSE:MRK) is also pursuing strategic growth through acquisitions, exemplified by its planned $10 billion purchase of Verona Pharma to expand its lung disease portfolio. While challenges persist with slowed HPV vaccine Gardasil uptake in markets like China and Japan, the business continues to optimize global operations and focus on innovative product launches.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.